Bavarian unconcerned by Moderna RSV advance: ”It's completely as expected"
Bavarian Nordic is not worried by the news that Moderna has announced a phase III trial of its RSV vaccine, positioning the US-based firm ahead of the Danish one in the race to reach the potentially lucrative RSV market. ”Old news,” says VP of Investor Relations & Communications Rolf Sass Sørensen.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Another competitor is now breathing down Bavarian Nordic’s neck, as Moderna announced its next step after a successful phase II with its vaccine against respiratory syncytial virus (RSV) on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Moderna initiates phase III study of RSV vaccine
For subscribers
Glaxosmithkline halts RSV trial after safety recommendation
For subscribers
Bavarian Nordic on FDA special status: A huge validation
For subscribers
.jpg&w=384&q=75)
